drugset / Trial / NCT00802880

Dacarbazine for Metastatic Soft Tissue and Bone Sarcoma

NCT00802880

Phase 2 Completed 80 enrolled Washington University School of Medicine
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine the overall best tumor response rate to dacarbazine given until disease progression as assessed by RECIST criteria, CT and clinical exams in patients with metastatic sarcomas.

Timeline

Start
2009-03
Primary completion
2015-01
Completion
2015-01

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Dacarbazine Small molecule 850 mg/m2 Intravenous

Indications